vchal / iStockphoto.com

17 January 2018Europe

Broad Institute to appeal CRISPR patent revocation

The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office (EPO) to revoke one of its patents covering CRISPR/Cas9 technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

Biotechnology

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

4 November 2019 The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

USPTO rules Broad owns CRISPR animal cell editing patents

1 March 2022 Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.

More on this story

USPTO rules Broad owns CRISPR animal cell editing patents

1 March 2022 Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.

Biotechnology

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

4 November 2019 The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More on this story

USPTO rules Broad owns CRISPR animal cell editing patents

1 March 2022 Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.

Biotechnology

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

4 November 2019 The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner